NxStage Medical, Inc. - FORM 8-K - June 1, 2011

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 1, 2011 (May 26, 2011)
NxSTAGE MEDICAL, INC.
(Exact name of registrant as specified in its charter)
         
         
Delaware   000-51567   04-3454702
(State or other jurisdiction of   (Commission File Number)   (I.R.S. Employer Identification No.)
incorporation or organization)        
     
439 S. Union St, 5th Floor, Lawrence, MA   01843
(Address of principal executive offices)   (Zip Code)
(978) 687-4700
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 

 

 

ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
We held our Annual Meeting of Stockholders on May 26, 2011. For more information on the following proposals, see our definitive Proxy Statement filed with the SEC on April 28, 2011.
Our stockholders elected by a majority of the votes cast each of the eight nominees to the Board of Directors to serve until our 2012 Annual Meeting of Stockholders, as follows:
                         
                    Broker
          Director   For   Withheld   Non-Votes
Jeffrey H. Burbank
     44,565,182       418,622       6,998,741  
Philippe O. Chambon
     41,996,641       2,987,163       6,998,741  
Daniel A. Giannini
     44,946,707       37,097       6,998,741  
Nancy J. Ham
     44,952,464       31,340       6,998,741  
Earl R. Lewis
     27,770,471       17,213,333       6,998,741  
Craig W. Moore
     42,407,450       2,576,354       6,998,741  
Reid S. Perper
     44,947,674       36,130       6,998,741  
David S. Utterberg
     44,563,764       420,040       6,998,741  
Our stockholders approved by a majority vote an amendment to the Company’s 2005 Stock Incentive Plan by the following vote, as follows:
         
For
    37,139,112  
Against
    7,786,573  
Abstain
    58,119  
Broker Non-Votes
    6,998,741  
Our stockholders approved, on a non-binding advisory basis, our named executive officers’ compensation as disclosed in the Proxy Statement, and the voting results were as follows:
         
For
    43,557,342  
Against
    1,392,831  
Abstain
    33,631  
Broker Non-Votes
    6,998,741  
Our stockholders voted, on a non-binding advisory basis, to hold future non-binding advisory votes on our named executive officers’ compensation once every year.
         
For 1-Year Term
     40,556,228  
For 2-Year Term
     100,397  
For 3-Year Term
     4,293,986  
Abstain
     33,193  
Broker Non-Votes
     6,998,741  

2

 

Our stockholders ratified the appointment of Ernst & Young LLP to serve as our independent registered public accounting firm for the fiscal year ending December 31, 2011 by the following vote, as follows:
         
For
    51,496,575  
Against
    465,651  
Abstain
    20,319  
Broker Non-Votes
    -0-  

3

 

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.
             
    NxStage Medical, Inc.    
 
            
Date: June 1, 2011
  By:   /s/ Robert S. Brown
 
    
        Robert S. Brown    
        Chief Financial Officer and Senior Vice President    

4

NxStage Medical, Inc. Reports

Also read